Date of Award

2020

Degree Name

Master of Medical Science (Physician Assistant)

Department

Physician Assistant; College of Health Sciences

First Advisor

Jodi Freeman

Abstract

Patients with moderate-severe asthma are dependent on beta-agonists and inhaled corticosteroids for maintenance, and oral corticosteroids for acute exacerbations. New approaches to the treatment of moderate-severe asthma have emerged, including agents that target interleukin-4, a key player in the inflammatory pathway of asthma. These medicines include Dupilumab and Pitrakinra. This study found that dupilumab is effective in controlling asthma symptoms and was recently FDA approved for treatment of moderate-severe asthma in those 12 years old and older, but studies of pitrakinra have ceased.

Additional Files

Ortega_PICO.mp4 (18211 kB)
Ortega_References.pdf (153 kB)

Share

COinS
 

Efficacy of Interleukin-4 Receptor Monocloncal Antibody (Dupilumab) and Interleukin-4 Antagonist (Pitrakinra) in the Treatment of Moderate-Severe Asthma

Patients with moderate-severe asthma are dependent on beta-agonists and inhaled corticosteroids for maintenance, and oral corticosteroids for acute exacerbations. New approaches to the treatment of moderate-severe asthma have emerged, including agents that target interleukin-4, a key player in the inflammatory pathway of asthma. These medicines include Dupilumab and Pitrakinra. This study found that dupilumab is effective in controlling asthma symptoms and was recently FDA approved for treatment of moderate-severe asthma in those 12 years old and older, but studies of pitrakinra have ceased.